The FDA announced today that they are upgrading to their highest level the warning associated with Singulair (Montelukast).

Singulair is a common once-a-day pill prescribed to asthma and allergic rhinitis patients that prevents your body from processing the chemical released when you breathe in an allergen.

Per the FDA, while there has been a stated side effect of change of mood, they are upgrading the warning due to increased reports of mental health impacts, including completed suicides.

From experience when being offered this drug for O, potential mental health impacts were not discussed. If you were in a similar boat, now may be a good time to consult with your doctor to re-evaluate if this is the best treatment option for you.